X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with ALEMBIC LTD - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs ALEMBIC LTD - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

ALEMBIC LTD 
   Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA ALEMBIC LTD AUROBINDO PHARMA/
ALEMBIC LTD
 
P/E (TTM) x 14.9 54.1 27.4% View Chart
P/BV x 3.0 2.2 138.5% View Chart
Dividend Yield % 0.4 0.5 88.6%  

Financials

 AUROBINDO PHARMA   ALEMBIC LTD
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-18
ALEMBIC LTD
Mar-18
AUROBINDO PHARMA/
ALEMBIC LTD
5-Yr Chart
Click to enlarge
High Rs80972 1,123.6%   
Low Rs50434 1,486.7%   
Sales per share (Unadj.) Rs281.14.7 5,979.2%  
Earnings per share (Unadj.) Rs41.46.1 677.5%  
Cash flow per share (Unadj.) Rs50.96.2 814.7%  
Dividends per share (Unadj.) Rs2.500.20 1,250.0%  
Dividend yield (eoy) %0.40.4 100.8%  
Book value per share (Unadj.) Rs199.440.7 490.3%  
Shares outstanding (eoy) m585.88267.03 219.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.311.3 20.7%   
Avg P/E ratio x15.98.7 183.0%  
P/CF ratio (eoy) x12.98.5 152.2%  
Price / Book Value ratio x3.31.3 252.9%  
Dividend payout %6.03.3 184.5%   
Avg Mkt Cap Rs m384,63014,139 2,720.3%   
No. of employees `00017.3NA-   
Total wages/salary Rs m21,308207 10,274.1%   
Avg. sales/employee Rs Th9,500.7NM-  
Avg. wages/employee Rs Th1,229.4NM-  
Avg. net profit/employee Rs Th1,397.9NM-  
INCOME DATA
Net Sales Rs m164,6661,255 13,118.7%  
Other income Rs m1,020370 275.5%   
Total revenues Rs m165,6861,625 10,193.5%   
Gross profit Rs m37,718111 33,949.1%  
Depreciation Rs m5,58038 14,761.1%   
Interest Rs m7772 45,717.6%   
Profit before tax Rs m32,380442 7,329.2%   
Minority Interest Rs m310-   
Prior Period Items Rs m01,212 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m8,18324 34,165.8%   
Profit after tax Rs m24,2291,630 1,486.6%  
Gross profit margin %22.98.9 258.8%  
Effective tax rate %25.35.4 466.2%   
Net profit margin %14.7129.8 11.3%  
BALANCE SHEET DATA
Current assets Rs m121,8781,867 6,527.7%   
Current liabilities Rs m86,806591 14,683.1%   
Net working cap to sales %21.3101.6 21.0%  
Current ratio x1.43.2 44.5%  
Inventory Days Days13094 137.8%  
Debtors Days Days6874 93.0%  
Net fixed assets Rs m81,0371,791 4,524.9%   
Share capital Rs m586534 109.7%   
"Free" reserves Rs m116,21810,324 1,125.7%   
Net worth Rs m116,80410,858 1,075.8%   
Long term debt Rs m4,51241 10,951.5%   
Total assets Rs m211,05211,591 1,820.9%  
Interest coverage x42.7260.9 16.4%   
Debt to equity ratio x00 1,018.0%  
Sales to assets ratio x0.80.1 720.4%   
Return on assets %11.814.1 84.2%  
Return on equity %20.715.0 138.2%  
Return on capital %27.415.2 180.1%  
Exports to sales %01.5 0.0%   
Imports to sales %021.0 0.0%   
Exports (fob) Rs mNA19 0.0%   
Imports (cif) Rs mNA263 0.0%   
Fx inflow Rs m80,72719 416,119.6%   
Fx outflow Rs m34,700264 13,153.0%   
Net fx Rs m46,027-244 -18,831.1%   
CASH FLOW
From Operations Rs m19,548236 8,290.2%  
From Investments Rs m-19,570-224 8,736.4%  
From Financial Activity Rs m8,642-27 -32,486.8%  
Net Cashflow Rs m8,922-15 -60,284.5%  

Share Holding

Indian Promoters % 54.1 64.0 84.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 0.2 3,975.0%  
FIIs % 27.7 9.7 285.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 26.1 39.1%  
Shareholders   69,601 54,701 127.2%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   GSK PHARMA  ALKEM LABORATORIES  AJANTA PHARMA  NOVARTIS  DR. DATSONS LABS  

Compare AUROBINDO PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Over 300 Points Higher; Energy and Metal Stocks Witness Buying(Closing)

After opening the day marginally lower, Indian share markets witnessed most of the buying interest during closing hours and ended their trading session on a strong note.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

ALEMBIC LTD Announces Quarterly Results (4QFY19); Net Profit Down 14.6% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, ALEMBIC LTD has posted a net profit of Rs 40 m (down 14.6% YoY). Sales on the other hand came in at Rs 253 m (down 23.8% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (up 19.3% YoY). Sales on the other hand came in at Rs 53 bn (up 21.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

ALEMBIC LTD Announces Quarterly Results (3QFY19); Net Profit Down 41.9% (Quarterly Result Update)

Feb 1, 2019 | Updated on Feb 1, 2019

For the quarter ended December 2018, ALEMBIC LTD has posted a net profit of Rs 32 m (down 41.9% YoY). Sales on the other hand came in at Rs 243 m (down 18.8% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

AUROBINDO PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of AUROBINDO PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

More Views on News

Most Popular

7 Stocks That Will Remain Evergreen in this Era of Technological Disruption(The 5 Minute Wrapup)

Jun 13, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

Kenneth Andrade Would Like Our Real Estate Stock Recommendation with Triple Digit Upside(The 5 Minute Wrapup)

Jun 12, 2019

This real estate stock recommended in Smart Money Secrets offers the most favourable upside potential.

Why I Believe Smallcaps Will Catch up to the Sensex(Profit Hunter)

Jun 14, 2019

Smallcaps have gone nowhere even as the Sensex makes new all-time highs. Find out why Richa believes this a good opportunity to invest in smallcaps.

Why Super Investor Kenneth Andrade is Bullish on Agri Stocks...and So Are We(The 5 Minute Wrapup)

Jun 21, 2019

Andrade gives his take on agriculture, an industry from which we have already recommended two stocks.

7 Bluechips to Profit from Tech Disruption(Profit Hunter)

Jun 17, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Jun 25, 2019 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 8-QTR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS